Novo Nordisk A/S ( NVO ) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes.

The update marks the first evaluation of amycretin in people with type 2 diabetes.

Novo Nordisk ( NVO ) is planning to initiate a phase 3 development program with amycretin for adults with type 2 diabetes in 2026. In June, the company said it planned to initiate a phase 3 development for amycretin for adults with overweight or obesity in the first quarter of 2026.

The trial evaluated once-weekly subcutaneous amycretin and once-daily oral amycretin compared with placebo in 448 patients with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor as standard of care.

Approximately 40% of all participants were using an SGLT2 inhibitor before initiating the trial.

SGLT2 inhibitors are a class of prescription medications used to treat type 2 diabetes by causing the kidneys to remove excess glucose from the body through urine.  

The trial was a combined multiple-ascending-dose study investigating six subcutaneous doses ranging from 0.4 mg to 40 mg administered weekly, and three daily oral doses of 6 mg, 25 mg, and 50 mg, with a total treatment duration of up to 36 weeks.

Also Read: Novo Nordisk’s Blockbuster Weight-Loss Drug Flops In Alzheimer’s Trial

When evaluating the effects of treatment, if everyone adhered to treatment from a mean baseline HbA1c (blood sugar level) of 7.8%, once-weekly subcutaneous amycretin achieved dose-dependent reductions in HbA1c of up to -1.8% by week 36.

The proportions of people achieving HbA1c